La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
75 hedge funds and large institutions have $219M invested in La Jolla Pharmaceutical Company in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 26 increasing their positions, 18 reducing their positions, and 14 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 18
17% more call options, than puts
Call options by funds: $717K | Put options by funds: $611K
6% less funds holding
Funds holding: 80 → 75 (-5)
13% less capital invested
Capital invested by funds: $252M → $219M (-$33.5M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$4.06M |
| 2 |
SG Americas Securities
New York
|
+$2.83M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$1.89M |
| 4 |
D.E. Shaw & Co
New York
|
+$1.06M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$803K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$12.1M |
| 2 |
Millennium Management
New York
|
-$6.86M |
| 3 |
BC
Broadfin Capital
New York
|
-$6.71M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$4.71M |
| 5 |
FI
Fosun International
Hong Kong,
China
|
-$3.74M |
LJPC Hedge Fund Activity: Q3 2019 in Review
75 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q3 2019, worth a combined $219M — down 13% from $252M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of LJPC and 10 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 26 added.
The largest buyer was Morgan Stanley, adding an estimated $4.06M. The largest seller was Sio Capital Management, exiting entirely with an estimated $12.1M sold.
- 75 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q3 2019, down from 80 in Q2 2019.
- Funds reported $219M of La Jolla Pharmaceutical Company stock for Q3 2019, down 13% quarter-over-quarter.
- 10 funds opened new La Jolla Pharmaceutical Company positions in Q3 2019 and 14 closed out, a net change of -4 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q3 2019 was Morgan Stanley, an estimated $4.06M added.
- The largest La Jolla Pharmaceutical Company seller in Q3 2019 was Sio Capital Management, an estimated $12.1M sold.
Based on aggregated 13F filings for Q3 2019.